Abstract
Our goal was to assess the patient-level burden among subjects with painful diabetic peripheral neuropathy (DPN). Community-based physicians recruited patients with painful DPN (N = 255) between April and October 2003. Patients completed a survey on pain experience (Brief Pain Inventory-DPN [BPI-DPN]), health status (EuroQoL [EQ-5D]), healthcare utilization (consults, prescription [Rx], and over-the-counter [OTC] medications), and work productivity/functioning. Patients were 61 ± 12.8 years old and had diabetes for 12 ± 10.3 years and painful DPN for 6.4 ± 6.4 years; 25.5 and 62.7% had other neuropathic and musculoskeletal pain conditions. Average and worst pain scores (BPI-DPN, 0-10 scales) were 5.0 ± 2.5 and 5.6 ± 2.8. The mean EQ-5D utility was .5 ± .3 (range = -.594-1). A majority (87.4%) took pain medications (Rx/OTC) in the preceding week: an average of 3.8 ± 3.9 Rx and 2.1 ± 1.3 OTC medications. Nearly half (46.7%) received NSAIDs. Other frequently reported medications were short/long-acting opioids (43.1%), anticonvulsants (27.1%), selective serotonin reuptake inhibitors/selective norepinephrine reuptake inhibitors (18%), and tricyclic antidepressants (11.4%). During the preceding 3 months, 59.6% had ≥2 health professional consults; 59% reported decreased home productivity; 85.5% reported activity limitations; and 64.4% of patients who worked (N = 73) reported missing work/decreased work productivity due to painful DPN. Our results underscore a substantial patient-level burden among subjects with painful DPN. Perspective: Information on the patient-level burden among painful DPN sufferers in the U.S. was previously lacking. Our results suggest that this burden is significant, evidenced by moderate-to-high pain levels, polypharmacy, health resource use, and work/activity limitations. Results also suggest suboptimal pain management and low levels of satisfaction with treatments.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 892-900 |
| Number of pages | 9 |
| Journal | Journal of Pain |
| Volume | 7 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2006 |
Fingerprint
Keywords
- burden of illness
- economic burden
- health surveys
- human burden
- pain experience
- Painful diabetic peripheral neuropathy
ASJC Scopus subject areas
- Anesthesiology and Pain Medicine
- Clinical Neurology
- Neurology
- Nursing(all)
Cite this
Burden of Illness in Painful Diabetic Peripheral Neuropathy : The Patients' Perspectives. / Gore, Mugdha; Brandenburg, Nancy A.; Hoffman, Deborah L.; Tai, Kei Sing; Stacey, Brett.
In: Journal of Pain, Vol. 7, No. 12, 12.2006, p. 892-900.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Burden of Illness in Painful Diabetic Peripheral Neuropathy
T2 - The Patients' Perspectives
AU - Gore, Mugdha
AU - Brandenburg, Nancy A.
AU - Hoffman, Deborah L.
AU - Tai, Kei Sing
AU - Stacey, Brett
PY - 2006/12
Y1 - 2006/12
N2 - Our goal was to assess the patient-level burden among subjects with painful diabetic peripheral neuropathy (DPN). Community-based physicians recruited patients with painful DPN (N = 255) between April and October 2003. Patients completed a survey on pain experience (Brief Pain Inventory-DPN [BPI-DPN]), health status (EuroQoL [EQ-5D]), healthcare utilization (consults, prescription [Rx], and over-the-counter [OTC] medications), and work productivity/functioning. Patients were 61 ± 12.8 years old and had diabetes for 12 ± 10.3 years and painful DPN for 6.4 ± 6.4 years; 25.5 and 62.7% had other neuropathic and musculoskeletal pain conditions. Average and worst pain scores (BPI-DPN, 0-10 scales) were 5.0 ± 2.5 and 5.6 ± 2.8. The mean EQ-5D utility was .5 ± .3 (range = -.594-1). A majority (87.4%) took pain medications (Rx/OTC) in the preceding week: an average of 3.8 ± 3.9 Rx and 2.1 ± 1.3 OTC medications. Nearly half (46.7%) received NSAIDs. Other frequently reported medications were short/long-acting opioids (43.1%), anticonvulsants (27.1%), selective serotonin reuptake inhibitors/selective norepinephrine reuptake inhibitors (18%), and tricyclic antidepressants (11.4%). During the preceding 3 months, 59.6% had ≥2 health professional consults; 59% reported decreased home productivity; 85.5% reported activity limitations; and 64.4% of patients who worked (N = 73) reported missing work/decreased work productivity due to painful DPN. Our results underscore a substantial patient-level burden among subjects with painful DPN. Perspective: Information on the patient-level burden among painful DPN sufferers in the U.S. was previously lacking. Our results suggest that this burden is significant, evidenced by moderate-to-high pain levels, polypharmacy, health resource use, and work/activity limitations. Results also suggest suboptimal pain management and low levels of satisfaction with treatments.
AB - Our goal was to assess the patient-level burden among subjects with painful diabetic peripheral neuropathy (DPN). Community-based physicians recruited patients with painful DPN (N = 255) between April and October 2003. Patients completed a survey on pain experience (Brief Pain Inventory-DPN [BPI-DPN]), health status (EuroQoL [EQ-5D]), healthcare utilization (consults, prescription [Rx], and over-the-counter [OTC] medications), and work productivity/functioning. Patients were 61 ± 12.8 years old and had diabetes for 12 ± 10.3 years and painful DPN for 6.4 ± 6.4 years; 25.5 and 62.7% had other neuropathic and musculoskeletal pain conditions. Average and worst pain scores (BPI-DPN, 0-10 scales) were 5.0 ± 2.5 and 5.6 ± 2.8. The mean EQ-5D utility was .5 ± .3 (range = -.594-1). A majority (87.4%) took pain medications (Rx/OTC) in the preceding week: an average of 3.8 ± 3.9 Rx and 2.1 ± 1.3 OTC medications. Nearly half (46.7%) received NSAIDs. Other frequently reported medications were short/long-acting opioids (43.1%), anticonvulsants (27.1%), selective serotonin reuptake inhibitors/selective norepinephrine reuptake inhibitors (18%), and tricyclic antidepressants (11.4%). During the preceding 3 months, 59.6% had ≥2 health professional consults; 59% reported decreased home productivity; 85.5% reported activity limitations; and 64.4% of patients who worked (N = 73) reported missing work/decreased work productivity due to painful DPN. Our results underscore a substantial patient-level burden among subjects with painful DPN. Perspective: Information on the patient-level burden among painful DPN sufferers in the U.S. was previously lacking. Our results suggest that this burden is significant, evidenced by moderate-to-high pain levels, polypharmacy, health resource use, and work/activity limitations. Results also suggest suboptimal pain management and low levels of satisfaction with treatments.
KW - burden of illness
KW - economic burden
KW - health surveys
KW - human burden
KW - pain experience
KW - Painful diabetic peripheral neuropathy
UR - http://www.scopus.com/inward/record.url?scp=33845221482&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845221482&partnerID=8YFLogxK
U2 - 10.1016/j.jpain.2006.04.013
DO - 10.1016/j.jpain.2006.04.013
M3 - Article
VL - 7
SP - 892
EP - 900
JO - Journal of Pain
JF - Journal of Pain
SN - 1526-5900
IS - 12
ER -